[Experience using sinakten-retard in the treatment of muscular sclerosis].
The experience of the authors demonstrated that the best results in sinakten-retard treatment were attained in patients with mild and moderate degrees of severity of the disease. However, even in patients with a protracted development, treatment by sinakten-retard increased the muscular strength in the paralyzed extremities, diminished the increased muscular tone and increased the volume of movements. All these facts permit the authors to recommend sinakten-retard for the treatment of disseminated sclerosis.
D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000293:Adolescent; D000302:Adrenal Cortex / Q000503:physiopathology; D000324:Adrenocorticotropic Hormone / Q000031:analogs & derivatives*; D000328:Adult; D003366:Cosyntropin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004644:Emotions; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D009128:Muscle Spasticity / Q000188:drug therapy; D009129:Muscle Tonus; D012075:Remission, Spontaneous
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D003692:Delayed-Action Preparations; D003366:Cosyntropin; D000324:Adrenocorticotropic Hormone
Opyt primeniia sinakten-retard dlia lecheniia rasseiannogo skleroza.